Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

5(83.3%)

Phase 2

1(16.7%)

6Total

Phase 1(5)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04524871Phase 1Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Role: collaborator

NCT06586957Phase 1Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Role: lead

NCT07029399Phase 1Recruiting

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Role: lead

NCT05935748Phase 2Terminated

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Role: lead

NCT05119335Phase 1Terminated

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Role: lead

NCT06264921Phase 1Terminated

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Role: lead

All 6 trials loaded